Dupilumab in children and adolescents with atopic dermatitis, a 52-week real-life experience: first report in Colombia
Atopic dermatitis (AD) is a chronic inflammatory disease characterized by relapsing eczema and pruritus. Recently, dupilumab has shown to be safe and improve symptoms of moderate to severe AD in adolescents up to 52 weeks, however, very few Latin American patients were included, so comprehensive re...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Asociación Colombiana de Dermatología y Cirugía Dermatológica
2024-10-01
|
| Series: | Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica |
| Subjects: | |
| Online Access: | https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Atopic dermatitis (AD) is a chronic inflammatory disease characterized by relapsing eczema and pruritus. Recently, dupilumab has shown to be safe and improve symptoms of moderate to severe AD in adolescents up to 52 weeks, however, very few Latin American patients were included, so comprehensive real-world data is needed. To our knowledge, there are no real-world studies published in this ethnicity regarding long-term treatment with Dupilumab for AD in adolescents.
|
|---|---|
| ISSN: | 1657-0448 2590-843X |